EE270 Cost-Effectiveness Evaluation of Sequential Treatment Stategies for Treatment Naïve Patients With BRAF Mutant Metastatic Melanoma in UK: Nivolumab Plus Ipilimumab First-Line Versus Dabrafenib Plus Trametinib First-Line
Abstract
Authors
A Tokarz R Cai B. Baginska-Dudek G Yates S Srinivasan G Okorogheye J Palaia L McDonald